;PMID: 11241321
;source_file_670.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:43..134] = [t:43..134]
;2)section:[e:138..187] = [t:138..187]
;3)section:[e:191..307] = [t:191..307]
;4)sentence:[e:311..483] = [t:311..483]
;5)sentence:[e:484..605] = [t:484..605]
;6)sentence:[e:606..802] = [t:606..802]
;7)sentence:[e:803..1022] = [t:803..1022]
;8)sentence:[e:1023..1179] = [t:1023..1179]
;9)sentence:[e:1180..1288] = [t:1180..1288]
;10)sentence:[e:1289..1483] = [t:1289..1483]
;11)sentence:[e:1484..1615] = [t:1484..1615]
;12)sentence:[e:1616..1704] = [t:1616..1704]
;13)sentence:[e:1705..1866] = [t:1705..1866]
;14)sentence:[e:1868..1951] = [t:1868..1951]
;15)sentence:[e:1952..2149] = [t:1952..2149]
;16)section:[e:2150..2182] = [t:2150..2182]
;17)section:[e:2186..2231] = [t:2186..2231]

;section 0 Span:0..38
;Int J Cancer  2001 Mar 20;95(2):108-13
(SEC
  (FRAG (NNP:[0..3] Int) (NNP:[4..5] J) (NNP:[6..12] Cancer) (CD:[14..18] 2001)
        (CC:[19..22] Mar) ($:[23..29] 20;95-LRB-) (CD:[29..30] 2)
        (-RRB-:[30..31] -RRB-) (CD:[31..35] :108) (HYPH:[35..36] -)
        (CD:[36..38] 13)))

;sentence 1 Span:43..134
;Altered expression and mutation of beta-catenin gene in gastric carcinomas
;and  cell lines.
;[78..90]:gene-rna:"beta-catenin"
;[99..117]:malignancy:"gastric carcinomas"
;[99..106]...[123..133]:malignancy:"gastric"..."cell lines"
(SENT
  (NP-HLN
    (NP
      (NP (VBN:[43..50] Altered) (NN:[51..61] expression))
      (CC:[62..65] and)
      (NP (NN:[66..74] mutation)))
    (PP (IN:[75..77] of)
      (NP (NN:[78..90] beta-catenin) (NN:[91..95] gene)))
    (PP-LOC (IN:[96..98] in)
      (NP
        (NP
          (ADJP-1 (JJ:[99..106] gastric))
          (NNS:[107..117] carcinomas))
        (CC:[118..121] and)
        (NP
          (ADJP-1 (-NONE-:[121..121] *P*))
          (NN:[123..127] cell) (NNS:[128..133] lines))))
    (.:[133..134] .)))

;section 2 Span:138..187
;Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH.
(SEC
  (FRAG (NNP:[138..141] Woo) (NNP:[142..144] DK) (,:[144..145] ,)
        (NNP:[146..149] Kim) (NNP:[150..152] HS) (,:[152..153] ,)
        (NNP:[154..157] Lee) (NNP:[158..160] HS) (,:[160..161] ,)
        (NNP:[162..166] Kang) (NNP:[167..169] YH) (,:[169..170] ,)
        (NNP:[171..175] Yang) (NNP:[176..178] HK) (,:[178..179] ,)
        (NNP:[180..183] Kim) (NNP:[184..187] WH.)))

;section 3 Span:191..307
;Department of Pathology and Cancer Research Institute, Seoul National
;University  College of Medicine, Seoul, Korea.
(SEC
  (FRAG (NNP:[191..201] Department) (IN:[202..204] of)
        (NNP:[205..214] Pathology) (CC:[215..218] and) (NNP:[219..225] Cancer)
        (NNP:[226..234] Research) (NNP:[235..244] Institute) (,:[244..245] ,)
        (NNP:[246..251] Seoul) (NNP:[252..260] National)
        (NNP:[261..271] University) (NNP:[273..280] College) (IN:[281..283] of)
        (NNP:[284..292] Medicine) (,:[292..293] ,) (NNP:[294..299] Seoul)
        (,:[299..300] ,) (NNP:[301..306] Korea) (.:[306..307] .)))

;sentence 4 Span:311..483
;beta-catenin serves not only as a structural component of the 
;E-cadherin-mediated cell-cell adhesion system, but also as a signaling
;molecule  of the Wnt/wingless pathway.
;[311..323]:gene-protein:"beta-catenin"
;[374..384]:gene-protein:"E-cadherin"
;[462..465]:gene-generic:"Wnt"
;[466..474]:gene-generic:"wingless"
(SENT
  (S
    (NP-SBJ (NN:[311..323] beta-catenin))
    (VP (VBZ:[324..330] serves)
      (PP
        (CONJP (RB:[331..334] not) (RB:[335..339] only))
        (PP (IN:[340..342] as)
          (NP
            (NP (DT:[343..344] a) (JJ:[345..355] structural)
                (NN:[356..365] component))
            (PP (IN:[366..368] of)
              (NP (DT:[369..372] the)
                (ADJP (NN:[374..384] E-cadherin) (HYPH:[384..385] -)
                      (VBN:[385..393] mediated))
                (NML
                  (NML (NN:[394..398] cell))
                  (PP (HYPH:[398..399] -)
                    (NP (NN:[399..403] cell))))
                (NN:[404..412] adhesion) (NN:[413..419] system)))))
        (,:[419..420] ,)
        (CONJP (CC:[421..424] but) (RB:[425..429] also))
        (PP (IN:[430..432] as)
          (NP
            (NP (DT:[433..434] a) (VBG:[435..444] signaling)
                (NN:[445..453] molecule))
            (PP (IN:[455..457] of)
              (NP (DT:[458..461] the)
                (NML (NN:[462..465] Wnt) (SYM:[465..466] /)
                     (JJ:[466..474] wingless))
                (NN:[475..482] pathway)))))))
    (.:[482..483] .)))

;sentence 5 Span:484..605
;Deregulated expression of beta-catenin and  mutations of the gene have been
;identified in a number of human malignancies.
;[510..522]:gene-protein:"beta-catenin"
;[545..549]:gene-rna:"gene"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (VBN:[484..495] Deregulated) (NN:[496..506] expression))
        (PP (IN:[507..509] of)
          (NP (NN:[510..522] beta-catenin))))
      (CC:[523..526] and)
      (NP
        (NP (NNS:[528..537] mutations))
        (PP (IN:[538..540] of)
          (NP (DT:[541..544] the) (NN:[545..549] gene)))))
    (VP (VBP:[550..554] have)
      (VP (VBN:[555..559] been)
        (VP (VBN:[560..570] identified)
          (NP-1 (-NONE-:[570..570] *))
          (PP (IN:[571..573] in)
            (NP
              (NP (DT:[574..575] a) (NN:[576..582] number))
              (PP (IN:[583..585] of)
                (NP (JJ:[586..591] human) (NNS:[592..604] malignancies))))))))
    (.:[604..605] .)))

;sentence 6 Span:606..802
;To  determine the role of beta-catenin defects in stomach cancer, we
;investigated  beta-catenin exon 3 mutations and altered protein expression in
;77 primary  gastric carcinomas and 11 cell lines.
;[632..644]:gene-generic:"beta-catenin"
;[656..670]:malignancy:"stomach cancer"
;[689..701]:gene-rna:"beta-catenin"
;[702..708]:variation-location:"exon 3"
;[709..718]:variation-event:"mutations"
;[731..738]:gene-protein:"protein"
;[756..783]:malignancy:"primary  gastric carcinomas"
;[765..772]...[791..801]:malignancy:"gastric"..."cell lines"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[606..606] *))
      (VP (TO:[606..608] To)
        (VP (VB:[610..619] determine)
          (NP
            (NP (DT:[620..623] the) (NN:[624..628] role))
            (PP (IN:[629..631] of)
              (NP (NN:[632..644] beta-catenin) (NNS:[645..652] defects))))
          (PP (IN:[653..655] in)
            (NP (NN:[656..663] stomach) (NN:[664..670] cancer))))))
    (,:[670..671] ,)
    (NP-SBJ (PRP:[672..674] we))
    (VP (VBD:[675..687] investigated)
      (NP
        (NP (NN:[689..701] beta-catenin)
          (NML (NN:[702..706] exon) (CD:[707..708] 3))
          (NNS:[709..718] mutations))
        (CC:[719..722] and)
        (NP (VBN:[723..730] altered) (NN:[731..738] protein)
            (NN:[739..749] expression)))
      (PP (IN:[750..752] in)
        (NP
          (NP (CD:[753..755] 77)
             (JJ:[756..763] primary) (JJ:[765..772] gastric)
             (NNS:[773..783] carcinomas))
          (CC:[784..787] and)
          (NP (CD:[788..790] 11) (NN:[791..795] cell) (NNS:[796..801] lines)))))
    (.:[801..802] .)))

;sentence 7 Span:803..1022
;In addition, the immunohistochemical  expression pattern of beta-catenin in
;303 consecutive gastric cancers was  determined and their relationships with
;clinicopathologic features and patient  outcome were investigated.
;[863..875]:gene-protein:"beta-catenin"
;[895..910]:malignancy:"gastric cancers"
(SENT
  (S
    (S
      (PP (IN:[803..805] In)
        (NP (NN:[806..814] addition)))
      (,:[814..815] ,)
      (NP-SBJ-2
        (NP (DT:[816..819] the) (JJ:[820..839] immunohistochemical)
            (NN:[841..851] expression) (NN:[852..859] pattern))
        (PP (IN:[860..862] of)
          (NP (NN:[863..875] beta-catenin)))
        (PP (IN:[876..878] in)
          (NP (CD:[879..882] 303) (JJ:[883..894] consecutive)
             (JJ:[895..902] gastric) (NNS:[903..910] cancers))))
      (VP (VBD:[911..914] was)
        (VP (VBN:[916..926] determined)
          (NP-2 (-NONE-:[926..926] *)))))
    (CC:[927..930] and)
    (S
      (NP-SBJ-1
        (NP (PRP$:[931..936] their) (NNS:[937..950] relationships))
        (PP (IN:[951..955] with)
          (NP
            (NP (JJ:[956..973] clinicopathologic) (NNS:[974..982] features))
            (CC:[983..986] and)
            (NP (NN:[987..994] patient) (NN:[996..1003] outcome)))))
      (VP (VBD:[1004..1008] were)
        (VP (VBN:[1009..1021] investigated)
          (NP-1 (-NONE-:[1021..1021] *)))))
    (.:[1021..1022] .)))

;sentence 8 Span:1023..1179
;This study revealed 5% (4 of 77) tumors and 27% (3 of  11) cell lines with
;beta-catenin gene alteration, 6 missense mutations, and 1  interstitial
;deletion.
;[1056..1062]:malignancy:"tumors"
;[1082..1092]:malignancy:"cell lines"
;[1098..1110]:gene-rna:"beta-catenin"
;[1111..1126]:variation-event:"gene alteration"
;[1130..1148]:variation-type:"missense mutations"
;[1157..1178]:variation-type:"interstitial deletion"
(SENT
  (S
    (NP-SBJ (DT:[1023..1027] This) (NN:[1028..1033] study))
    (VP (VBD:[1034..1042] revealed)
      (NP
        (NP
          (NP (CD:[1043..1044] 5) (NN:[1044..1045] %)
            (PRN (-LRB-:[1046..1047] -LRB-)
              (NP
                (NP (CD:[1047..1048] 4))
                (PP (IN:[1049..1051] of)
                  (NP (CD:[1052..1054] 77))))
              (-RRB-:[1054..1055] -RRB-))
            (NNS:[1056..1062] tumors))
          (CC:[1063..1066] and)
          (NP (CD:[1067..1069] 27) (NN:[1069..1070] %)
            (PRN (-LRB-:[1071..1072] -LRB-)
              (NP
                (NP (CD:[1072..1073] 3))
                (PP (IN:[1074..1076] of)
                  (NP (CD:[1078..1080] 11))))
              (-RRB-:[1080..1081] -RRB-))
             (NN:[1082..1086] cell) (NNS:[1087..1092] lines)))
        (PP (IN:[1093..1097] with)
          (NP
            (NP (NN:[1098..1110] beta-catenin)
               (NN:[1111..1115] gene) (NN:[1116..1126] alteration))
            (,:[1126..1127] ,)
            (NP
              (NP (CD:[1128..1129] 6)
                 (JJ:[1130..1138] missense) (NNS:[1139..1148] mutations))
              (,:[1148..1149] ,) (CC:[1150..1153] and)
              (NP (CD:[1154..1155] 1)
                 (JJ:[1157..1169] interstitial) (NN:[1170..1178] deletion)))))))
    (.:[1178..1179] .)))

;sentence 9 Span:1180..1288
;These genetic changes were shown to correlate closely  with nuclear
;localization of the protein (p = 0.001).
;[1186..1201]:variation-event:"genetic changes"
;[1268..1275]:gene-protein:"protein"
(SENT
  (S
    (NP-SBJ-1 (DT:[1180..1185] These)
       (JJ:[1186..1193] genetic) (NNS:[1194..1201] changes))
    (VP (VBD:[1202..1206] were)
      (VP (VBN:[1207..1212] shown)
        (S
          (NP-SBJ-1 (-NONE-:[1212..1212] *))
          (VP (TO:[1213..1215] to)
            (VP (VB:[1216..1225] correlate)
              (ADVP (RB:[1226..1233] closely))
              (PP-CLR (IN:[1235..1239] with)
                (NP
                  (NP (JJ:[1240..1247] nuclear) (NN:[1248..1260] localization))
                  (PP (IN:[1261..1263] of)
                    (NP (DT:[1264..1267] the) (NN:[1268..1275] protein)
                      (PRN (-LRB-:[1276..1277] -LRB-)
                        (S
                          (NP-SBJ (NN:[1277..1278] p))
                          (VP (SYM:[1279..1280] =)
                            (NP (CD:[1281..1286] 0.001))))
                        (-RRB-:[1286..1287] -RRB-)))))))))))
    (.:[1287..1288] .)))

;sentence 10 Span:1289..1483
;In an immunohistochemical  analysis, abnormal expressions of beta-catenin,
;such as nuclear accumulation and  loss of membranous distribution, were
;detected in 27% (81 of 303) of tumors  overall.
;[1350..1362]:gene-protein:"beta-catenin"
;[1467..1473]:malignancy:"tumors"
(SENT
  (S
    (PP (IN:[1289..1291] In)
      (NP (DT:[1292..1294] an) (JJ:[1295..1314] immunohistochemical)
          (NN:[1316..1324] analysis)))
    (,:[1324..1325] ,)
    (NP-SBJ-1
      (NP (JJ:[1326..1334] abnormal) (NNS:[1335..1346] expressions))
      (PP (IN:[1347..1349] of)
        (NP (NN:[1350..1362] beta-catenin)))
      (,:[1362..1363] ,)
      (PP (JJ:[1364..1368] such) (IN:[1369..1371] as)
        (NP
          (NP (JJ:[1372..1379] nuclear) (NN:[1380..1392] accumulation))
          (CC:[1393..1396] and)
          (NP
            (NP (NN:[1398..1402] loss))
            (PP (IN:[1403..1405] of)
              (NP (JJ:[1406..1416] membranous) (NN:[1417..1429] distribution)))))))
    (,:[1429..1430] ,)
    (VP (VBD:[1431..1435] were)
      (VP (VBN:[1436..1444] detected)
        (NP-1 (-NONE-:[1444..1444] *))
        (PP-LOC (IN:[1445..1447] in)
          (NP
            (NP (CD:[1448..1450] 27) (NN:[1450..1451] %)
              (PRN (-LRB-:[1452..1453] -LRB-)
                (NP
                  (NP (CD:[1453..1455] 81))
                  (PP (IN:[1456..1458] of)
                    (NP (CD:[1459..1462] 303))))
                (-RRB-:[1462..1463] -RRB-)))
            (PP (IN:[1464..1466] of)
              (NP (NNS:[1467..1473] tumors)))))
        (ADVP (RB:[1475..1482] overall))))
    (.:[1482..1483] .)))

;sentence 11 Span:1484..1615
;These altered beta-catenin expressions were more commonly observed in  37%
;(58 of 158) diffuse type gastric carcinomas (p < 0.001).
;[1498..1510]:gene-protein:"beta-catenin"
;[1571..1602]:malignancy:"diffuse type gastric carcinomas"
(SENT
  (S
    (NP-SBJ-1 (DT:[1484..1489] These) (VBN:[1490..1497] altered)
              (NN:[1498..1510] beta-catenin) (NNS:[1511..1522] expressions))
    (VP (VBD:[1523..1527] were)
      (ADVP (RBR:[1528..1532] more) (RB:[1533..1541] commonly))
      (VP (VBN:[1542..1550] observed)
        (NP-1 (-NONE-:[1550..1550] *))
        (PP-LOC (IN:[1551..1553] in)
          (NP (CD:[1555..1557] 37) (NN:[1557..1558] %)
            (PRN (-LRB-:[1559..1560] -LRB-)
              (NP
                (NP (CD:[1560..1562] 58))
                (PP (IN:[1563..1565] of)
                  (NP (CD:[1566..1569] 158))))
              (-RRB-:[1569..1570] -RRB-))
            
            (NML (JJ:[1571..1578] diffuse) (NN:[1579..1583] type))
            (JJ:[1584..1591] gastric) (NNS:[1592..1602] carcinomas)))
        (PRN (-LRB-:[1603..1604] -LRB-)
          (S
            (NP-SBJ (NN:[1604..1605] p))
            (VP (SYM:[1606..1607] <)
              (NP (CD:[1608..1613] 0.001))))
          (-RRB-:[1613..1614] -RRB-))))
    (.:[1614..1615] .)))

;sentence 12 Span:1616..1704
;Loss of membranous  beta-catenin staining was associated with poor survival
;(p = 0.045).
;[1636..1648]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1616..1620] Loss))
      (PP (IN:[1621..1623] of)
        (NP (JJ:[1624..1634] membranous) (NN:[1636..1648] beta-catenin)
            (NN:[1649..1657] staining))))
    (VP (VBD:[1658..1661] was)
      (VP (VBN:[1662..1672] associated)
        (NP-1 (-NONE-:[1672..1672] *))
        (PP-CLR (IN:[1673..1677] with)
          (NP (JJ:[1678..1682] poor) (NN:[1683..1691] survival)))
        (PRN (-LRB-:[1692..1693] -LRB-)
          (S
            (NP-SBJ (NN:[1693..1694] p))
            (VP (SYM:[1695..1696] =)
              (NP (CD:[1697..1702] 0.045))))
          (-RRB-:[1702..1703] -RRB-))))
    (.:[1703..1704] .)))

;sentence 13 Span:1705..1866
;In  conclusion, our results demonstrate that beta-catenin mutations are
;common in  gastric cancer cell lines but occur infrequently in gastric
;carcinoma tissues.
;[1750..1762]:gene-rna:"beta-catenin"
;[1788..1813]:malignancy:"gastric cancer cell lines"
;[1840..1865]:malignancy:"gastric carcinoma tissues"
(SENT
  (S
    (PP (IN:[1705..1707] In)
      (NP (NN:[1709..1719] conclusion)))
    (,:[1719..1720] ,)
    (NP-SBJ (PRP$:[1721..1724] our) (NNS:[1725..1732] results))
    (VP (VBP:[1733..1744] demonstrate)
      (SBAR (IN:[1745..1749] that)
        (S
          (NP-SBJ (NN:[1750..1762] beta-catenin) (NNS:[1763..1772] mutations))
          (VP
            (VP (VBP:[1773..1776] are)
              (ADJP-PRD (JJ:[1777..1783] common)
                (PP (IN:[1784..1786] in)
                  (NP
                    (NML (JJ:[1788..1795] gastric) (NN:[1796..1802] cancer))
                    (NN:[1803..1807] cell) (NNS:[1808..1813] lines)))))
            (CC:[1814..1817] but)
            (VP (VBP:[1818..1823] occur)
              (ADVP (RB:[1824..1836] infrequently))
              (PP-LOC (IN:[1837..1839] in)
                (NP (JJ:[1840..1847] gastric) (NN:[1848..1857] carcinoma)
                    (NNS:[1858..1865] tissues))))))))
    (.:[1865..1866] .)))

;sentence 14 Span:1868..1951
;These mutations are one of the causes of the nuclear accumulation of 
;beta-catenin.
;[1874..1883]:variation-event:"mutations"
;[1938..1950]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ (DT:[1868..1873] These) (NNS:[1874..1883] mutations))
    (VP (VBP:[1884..1887] are)
      (NP-PRD
        (NP (CD:[1888..1891] one))
        (PP (IN:[1892..1894] of)
          (NP
            (NP (DT:[1895..1898] the) (NNS:[1899..1905] causes))
            (PP (IN:[1906..1908] of)
              (NP
                (NP (DT:[1909..1912] the) (JJ:[1913..1920] nuclear)
                    (NN:[1921..1933] accumulation))
                (PP (IN:[1934..1936] of)
                  (NP (NN:[1938..1950] beta-catenin)))))))))
    (.:[1950..1951] .)))

;sentence 15 Span:1952..2149
;Frequent abnormalities of beta-catenin expression in gastric  carcinoma
;support the idea that both structural and signaling functions of the  protein
;play a critical role in gastric carcinogenesis.
;[1978..1990]:gene-protein:"beta-catenin"
;[2005..2023]:malignancy:"gastric  carcinoma"
;[2094..2101]:gene-protein:"protein"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1952..1960] Frequent) (NNS:[1961..1974] abnormalities))
      (PP (IN:[1975..1977] of)
        (NP (NN:[1978..1990] beta-catenin) (NN:[1991..2001] expression)))
      (PP (IN:[2002..2004] in)
        (NP (JJ:[2005..2012] gastric) (NN:[2014..2023] carcinoma))))
    (VP (VBP:[2024..2031] support)
      (NP (DT:[2032..2035] the) (NN:[2036..2040] idea)
        (SBAR (IN:[2041..2045] that)
          (S
            (NP-SBJ
              (NP (CC:[2046..2050] both)
                (NP (JJ:[2051..2061] structural)
                  (NML-1 (-NONE-:[2061..2061] *P*)))
                (CC:[2062..2065] and)
                (NP (VBG:[2066..2075] signaling)
                  (NML-1 (NNS:[2076..2085] functions))))
              (PP (IN:[2086..2088] of)
                (NP (DT:[2089..2092] the) (NN:[2094..2101] protein))))
            (VP (VBP:[2102..2106] play)
              (NP (DT:[2107..2108] a) (JJ:[2109..2117] critical)
                  (NN:[2118..2122] role))
              (PP (IN:[2123..2125] in)
                (NP (JJ:[2126..2133] gastric) (NN:[2134..2148] carcinogenesis))))))))
    (.:[2148..2149] .)))

;section 16 Span:2150..2182
;Copyright 2001  Wiley-Liss, Inc.
(SEC
  (FRAG (NNP:[2150..2159] Copyright) (CD:[2160..2164] 2001)
        (NNP:[2166..2171] Wiley) (HYPH:[2171..2172] -) (NNP:[2172..2176] Liss)
        (,:[2176..2177] ,) (NNP:[2178..2182] Inc.)))

;section 17 Span:2186..2231
;PMID: 11241321 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2186..2190] PMID) (::[2190..2191] :) (CD:[2192..2200] 11241321)
        (-LRB-:[2201..2202] -LSB-) (NNP:[2202..2208] PubMed)
        (HYPH:[2209..2210] -) (JJ:[2211..2218] indexed) (IN:[2219..2222] for)
        (NNP:[2223..2230] MEDLINE) (-RRB-:[2230..2231] -RSB-)))
